Loading...
β’
Dec 31, 2022
Oncology Institute Q4 2022 Earnings Report
Reported financial results, highlighting a revenue increase of 36.6% and a gross profit increase of 87.6% compared to the prior year quarter.
Key Takeaways
The Oncology Institute (TOI) reported a 36.6% increase in consolidated revenue, reaching $71 million for Q4 2022. Gross profit increased by 87.6% to $16 million. The company ended the year with $132 million in cash, cash equivalents, and investments.
Consolidated revenue increased by 36.6% to $71 million.
Gross profit increased by 87.6% to $16 million.
Net loss decreased to $9.5 million from $10.2 million in the prior year quarter.
Ended the fiscal year with $132 million in cash, cash equivalents, and investments.
Oncology Institute
Oncology Institute
Oncology Institute Revenue by Segment
Revenue by Segment
Patient Services Revenue
CapyFin.comDispensary Revenue
CapyFin.comClinical Trials & Other Revenue
CapyFin.com Forward Guidance
The Oncology Institute expects revenue between $290 million and $320 million, gross profit between $60 million and $70 million, and Adjusted EBITDA between $(25) million and $(28) million for fiscal year 2023.
Positive Outlook
- Revenue is projected to grow by approximately 15% to 27% over 2022 revenue.
- Gross profit is expected to be between $60 million and $70 million.
- Value-based lives are expected to be between 1.75 million and 2.0 million.
- Interest expense is expected in the range of $4 million to $5 million.
- Depreciation and amortization is expected in the range of $4 million to $6 million.
Challenges Ahead
- Adjusted EBITDA is projected to be between $(25) million and $(28) million.
- Uncertainties regarding taxes.
- Share-based compensation.
- Goodwill impairment charges.
- Change in fair value of liabilities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income